Clinical Trial Update: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating switching to a fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-1 infec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bictegravir/Emtricitabine/Tenofovir Alafenamide (Bictegravir/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Vancouver Infectious Diseases Centre | Conditions: Human Immunodeficiency Virus I Infection, Drug Use | Phase 4 | Status: UNKNOWN